AQR Capital Management LLC bought a new position in Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 15,626 shares of the company’s stock, valued at approximately $113,000.
A number of other hedge funds have also made changes to their positions in the stock. Thoroughbred Financial Services LLC purchased a new stake in shares of Larimar Therapeutics in the second quarter worth approximately $94,000. EntryPoint Capital LLC purchased a new stake in shares of Larimar Therapeutics in the first quarter worth approximately $106,000. Virtu Financial LLC purchased a new stake in shares of Larimar Therapeutics in the first quarter worth approximately $133,000. Ballentine Partners LLC purchased a new stake in shares of Larimar Therapeutics in the second quarter worth approximately $137,000. Finally, Rhumbline Advisers lifted its position in shares of Larimar Therapeutics by 74.6% in the second quarter. Rhumbline Advisers now owns 54,936 shares of the company’s stock worth $398,000 after purchasing an additional 23,475 shares in the last quarter. 91.92% of the stock is owned by hedge funds and other institutional investors.
Larimar Therapeutics Stock Down 1.1 %
Shares of LRMR stock opened at $7.76 on Friday. Larimar Therapeutics, Inc. has a 12 month low of $2.18 and a 12 month high of $13.68. The business’s 50 day moving average is $7.32 and its two-hundred day moving average is $7.76. The company has a market cap of $495.10 million, a PE ratio of -8.00 and a beta of 0.98.
Analyst Ratings Changes
LRMR has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on shares of Larimar Therapeutics in a research report on Wednesday, October 2nd. They issued a “buy” rating and a $15.00 price target for the company. Robert W. Baird initiated coverage on shares of Larimar Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $16.00 price objective on the stock. Oppenheimer initiated coverage on shares of Larimar Therapeutics in a research report on Wednesday. They set an “outperform” rating and a $26.00 price objective on the stock. Wedbush initiated coverage on shares of Larimar Therapeutics in a research report on Thursday, October 3rd. They set an “outperform” rating and a $22.00 price objective on the stock. Finally, Baird R W raised shares of Larimar Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 4th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $20.43.
Check Out Our Latest Research Report on Larimar Therapeutics
Larimar Therapeutics Profile
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
Featured Stories
- Five stocks we like better than Larimar Therapeutics
- Consumer Discretionary Stocks Explained
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- 3 Fintech Stocks With Good 2021 Prospects
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Want to see what other hedge funds are holding LRMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report).
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.